Research community reports describe first measurable body composition changes at weeks 4 to 6, with peak effect at weeks 8 to 12
For secondary LONP1-related diseases, therapeutic targets can extend beyond LONP1 itself to upstream and downstream pathways, including MPC1 agonists for metabolic reprogramming, CYP11A1 inhibitors for hormone synthesis regulation, or TGF- inhibitors for fibrosis modulation
Originally reserved only for the severely ill, IV therapy, has over the years become more commonly utilized for preventative purposes and for people looking for fast recovery
R 10 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 7 heterocycloalkyl, C 6 -C 10 aryl, C 3 -C 9 heteroaryl, C 1 -C 6 alkylC 6 -C 10 aryl, or C 1 -C 6 alkylC 3 -C 9 heteroaryl